Share chart LENZ Therapeutics, Inc.
Extended chart
Simple chart
About LENZ Therapeutics, Inc.
LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.IPO date | 2021-06-25 |
---|---|
Industry | Biotechnology |
Sector | Health Care |
Валюта | usd |
Валюта отчета | usd |
Див.доход ао | 0 |
Дивиденд ао | 1.03 |
Сайт | https://www.lenz-tx.com |
Цена ао | 26.09 |
Change price per day: | -3.35% (26.53) |
---|---|
Change price per week: | -3.21% (26.49) |
Change price per month: | +16.65% (21.98) |
Change price per 3 month: | -18.14% (31.32) |
Change price per half year: | +8% (23.74) |
Change price per year: | +14.82% (22.33) |
Change price per 3 year: | +2 094.08% (1.1686) |
Change price per year to date: | -20.89% (32.41) |
|
Underestimation
|
Efficiency
|
|||||||||||||||||||||||||||||||||||||
Dividends
|
Debt
|
Growth impulse
|
Head | Job title | Payment | Year of birth |
---|---|---|---|
Mr. Evert B. Schimmelpennink | President, CEO, Secretary & Director | 886.54k | 1972 (53 years) |
Mr. Shawn Olsson | Chief Commercial Officer | 532.13k | 1983 (42 years) |
Mr. Marc G. Odrich M.D. | Chief Medical Officer | 576.95k | 1959 (66 years) |
Mr. James W. McCollum | Co-Founder & Director | N/A | 1955 (70 years) |
Mr. Daniel R. Chevallard CPA | Chief Financial Officer | N/A | 1979 (46 years) |
Mr. Domenick Porfidia | Vice President of Sales | N/A | |
Mr. David Murphy | Vice President of Marketing | N/A | |
Mr. Marvin J. Garrett | Senior Vice President of Regulatory & Quality | N/A | 1951 (74 years) |
Ms. Breianna Bowen | Vice President of Human Resources |
Address: United States, Del Mar. CA, 445 Marine View Avenue - open in Google maps, open in Yandex maps
Website: https://www.lenz-tx.com
Website: https://www.lenz-tx.com